Ushiyama T, Ihara H, Kurita Y, Kageyama S, Ueda D, Mugiya S, Yamaguchi Y, Nakano M, Suzuki K, Kawabe K
Department of Urology, Hamamatsu University School of Medicine.
Hinyokika Kiyo. 1993 Dec;39(12):1139-44.
Between August, 1986 and August, 1992, 16 combination chemotherapies with etoposide (100 mg/body, day 1-5), ifosfamide (50 mg/kg, day 1, 3, 5), peplomycin (5 mg/body, day 1-5) were performed on 13 patients with endocrine therapy-relapsed advanced prostatic cancer. Seven trials were performed on 5 patients who received DESP (diethylstilbestrol diphosphate) (500 mg/body, day 1-5) with the chemotherapy. In 9 trials performed on 9 patients who did not receive DESP, there was no response case. In 7 trials with DESP, one trial had a partial response (PR) (14%) and 4 remained objectively stable (stable) (57%). As to adverse effects, myelosuppression was observed in all trials but there was no lethal toxicity. The one-year survival rate of these patients treated with the chemotherapy alone and combined DESP were both about 20%. Therefore we should find a more effective treatment for endocrine relapsed prostatic cancer.
1986年8月至1992年8月期间，对13例内分泌治疗后复发的晚期前列腺癌患者进行了16次联合化疗，化疗方案为依托泊苷（100mg/体，第1 - 5天）、异环磷酰胺（50mg/kg，第1、3、5天）、培普利霉素（5mg/体，第1 - 5天）。对5例接受己烯雌酚二磷酸酯（DESP）（500mg/体，第1 - 5天）联合化疗的患者进行了7次试验。在对9例未接受DESP的患者进行的9次试验中，无反应病例。在7次使用DESP的试验中，1次试验有部分缓解（PR）（14%），4例客观上保持稳定（稳定）（57%）。关于不良反应，所有试验均观察到骨髓抑制，但无致命毒性。单纯化疗和联合DESP治疗的这些患者的一年生存率均约为20%。因此，我们应该为内分泌复发的前列腺癌寻找更有效的治疗方法。
